Market Cap 9.82M
Revenue (ttm) 170,000.00
Net Income (ttm) -16.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,758.82%
Debt to Equity Ratio 0.00
Volume 24,900
Avg Vol 93,502
Day's Range N/A - N/A
Shares Out 9.01M
Stochastic %K 35%
Beta 0.88
Analysts Hold
Price Target $4.00

Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens....

Industry: Biotechnology
Sector: Healthcare
Phone: 908 842 0100
Address:
110 Allen Road, 2nd Floor, Basking Ridge, United States
skyrockets_Inc
skyrockets_Inc Aug. 11 at 3:58 PM
$LSTA Exactly as I predicted in my post below. The lawsuit is leverage to get Kuva to complete the offer as is (or reduced). Both sides have confirmed to me via email they are still open to it and currently working on it. I emailed CEO two days ago and just double confirmed that the relationship is not soured because of the lawsuit. Here is his response: " The simple answer is “yes” to the openness to a “fully funded legitimate offer” from Kuva. The filing of the suit is to recoup damages to our shareholders for their breach of contract. It would seem that the simplest way for them to make the suit go away would be to complete the deal they offered. DJM "
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Aug. 7 at 5:52 PM
$LSTA Kuva will either have to pay $2M (+ litigation) and get nth or find the cash and close the deal
1 · Reply
skyrockets_Inc
skyrockets_Inc Aug. 7 at 5:35 PM
$LSTA 10Q shows 10m cash end of June 30, 2026. 1.2m in costs with workforce reduction, and burn of 3-4m in GA expenses puts this at 5m cash end of Sept 30, 2026. Likely has 7m in cash today + NASDAQ shell worth 7-10m. In an RM scenario the likely value would be 3m cash + NASDAQ shell = 10m or 1.10/share FLOOR valuation, giving ZERO value to assets. The math still supports the current PPS imo
0 · Reply
majsterJoda
majsterJoda Aug. 7 at 11:12 AM
$LSTA this should be priced below 50c
0 · Reply
majsterJoda
majsterJoda Aug. 7 at 11:10 AM
$LSTA cash 8 mil - 70% workforce retention bonusess ... we can say 5 mil
1 · Reply
TwongStocks
TwongStocks Aug. 6 at 8:20 PM
$LSTA 10-Q filed after hours today https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000032001726000038/lsta-20260630.htm • Cash is $10.44M as of June 30th. • They estimate that they will incur approximately $1.2 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits.
0 · Reply
majsterJoda
majsterJoda Aug. 6 at 12:12 PM
$LSTA they have less than 5mil cash this should fall soon
0 · Reply
skyrockets_Inc
skyrockets_Inc Aug. 4 at 5:36 PM
$LSTA PR today is in line w/ expectations of companies next steps. Proceed w/ litigation as discussed in previous filing, put pressure on Kuva (who is still actively working on funding) while proceeding w/ a secondary strategic alternative process likely looking for merger candidates. Option A). Kuva returns with FULLY FUNDED tender offer in 2.50-3.50/share range upfront --> LSTA accepts--> Stock pops--> Lawsuit dropped. Option B). Kuva does not return with offer, or returns with sub-par offer that LSTA rejects (i.e. $1/share range). --> Lawsuit proceeds --> LSTA finds RM candidate (5m in net cash + 5-7m in NASDAQ shell value puts deal value at $1.10/share MIN, w/ no value given to legacy assets). CFO is employed through Dec31 2026 so any deal will likely come months before then. Win-win solution either way imo.
0 · Reply
LandonCapital
LandonCapital Aug. 4 at 11:38 AM
$LSTA https://landoncapital.net/bad-breakups-lisata-nasdaq-lsta-sues-kuva-labs-after-merger-collapse/
0 · Reply
TwongStocks
TwongStocks Aug. 4 at 11:28 AM
$LSTA SEC filing this morning. Reduction in force by 72% effective immediately. https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000114036126031028/ef20079399_8k.htm • Chief Medical Officer, Kristen Buck, was let go. • Chief Accounting Officer, James Nisco, was given a $200K retention bonus for continued employment through Dec 31, 2026. • Lisata filed lawsuit against Kuva Labs in the Court of Chancery of the State of Delaware.
0 · Reply
Latest News on LSTA
Lisata Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 4:00 PM EDT - 10 days ago

Lisata Therapeutics Quarterly report: Q2 2026


Lisata Therapeutics terminates merger with Kuva Labs

2026-07-27T14:05:15.000Z - 20 days ago

Lisata Therapeutics terminates merger with Kuva Labs


Lisata Therapeutics downgraded to Hold from Buy at Brookline

2026-07-27T13:55:36.000Z - 20 days ago

Lisata Therapeutics downgraded to Hold from Buy at Brookline


Lisata Therapeutics Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Lisata Therapeutics Quarterly report: Q1 2026


Lisata Therapeutics Annual report: Q4 2025

Mar 12, 2026, 4:00 PM EDT - 5 months ago

Lisata Therapeutics Annual report: Q4 2025


Lisata Therapeutics downgraded to Hold from Buy at Brookline

2026-01-21T14:35:15.000Z - 7 months ago

Lisata Therapeutics downgraded to Hold from Buy at Brookline


Lisata Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Lisata Therapeutics Earnings Call Transcript: Q3 2025


Lisata Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Lisata Therapeutics Quarterly report: Q3 2025


Lisata Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Lisata Therapeutics Earnings release: Q3 2025


Lisata Therapeutics Slides: Corporate Presentation

Nov 6, 2025, 4:00 PM EST - 10 months ago

Lisata Therapeutics Slides: Corporate Presentation


Lisata Therapeutics Slides: Corporate Presentation

Oct 21, 2025, 7:00 AM EDT - 10 months ago

Lisata Therapeutics Slides: Corporate Presentation


Lisata Therapeutics to Present at LD Micro Main Event XIX

Oct 13, 2025, 8:00 AM EDT - 10 months ago

Lisata Therapeutics to Present at LD Micro Main Event XIX


Lisata Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q2 2025


Lisata Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Lisata Therapeutics Quarterly report: Q2 2025


Lisata Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Lisata Therapeutics Earnings release: Q2 2025


Lisata Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q1 2025


Lisata Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Lisata Therapeutics Quarterly report: Q1 2025


Lisata Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Lisata Therapeutics Earnings release: Q1 2025


Lisata Therapeutics Slides: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Lisata Therapeutics Slides: Q1 2025


Lisata Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Proxy statement: Proxy Filing


Lisata Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Proxy statement: Proxy Filing


Lisata Therapeutics announces research license with Catalent

2025-04-15T12:11:26.000Z - 1 year ago

Lisata Therapeutics announces research license with Catalent


Lisata Therapeutics Announces Research License with Catalent

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces Research License with Catalent


Lisata Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q4 2024


Lisata Therapeutics Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Lisata Therapeutics Annual report: Q4 2024


Lisata Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Lisata Therapeutics Earnings release: Q4 2024


Lisata Therapeutics Slides: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Lisata Therapeutics Slides: Q4 2024


Lisata Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q3 2024


Lisata Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Lisata Therapeutics Quarterly report: Q3 2024


Lisata Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Lisata Therapeutics Earnings release: Q3 2024


Lisata Therapeutics Slides: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Lisata Therapeutics Slides: Q3 2024


Lisata Therapeutics Transcript: LD Micro Main Event XVI

Oct 29, 2024, 2:00 PM EDT - 1 year ago

Lisata Therapeutics Transcript: LD Micro Main Event XVI


Lisata Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Lisata Therapeutics Earnings Call Transcript: Q2 2024


Lisata Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Lisata Therapeutics Quarterly report: Q2 2024


Lisata Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Lisata Therapeutics Earnings release: Q2 2024


Lisata Therapeutics Slides: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Lisata Therapeutics Slides: Q2 2024


Lisata Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Lisata Therapeutics Earnings Call Transcript: Q1 2024


Lisata Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Lisata Therapeutics Quarterly report: Q1 2024


Lisata Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Lisata Therapeutics Earnings release: Q1 2024


Lisata Therapeutics Slides: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Lisata Therapeutics Slides: Q1 2024


Lisata Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Lisata Therapeutics Proxy statement: Proxy Filing


Lisata Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Lisata Therapeutics Proxy statement: Proxy Filing


skyrockets_Inc
skyrockets_Inc Aug. 11 at 3:58 PM
$LSTA Exactly as I predicted in my post below. The lawsuit is leverage to get Kuva to complete the offer as is (or reduced). Both sides have confirmed to me via email they are still open to it and currently working on it. I emailed CEO two days ago and just double confirmed that the relationship is not soured because of the lawsuit. Here is his response: " The simple answer is “yes” to the openness to a “fully funded legitimate offer” from Kuva. The filing of the suit is to recoup damages to our shareholders for their breach of contract. It would seem that the simplest way for them to make the suit go away would be to complete the deal they offered. DJM "
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Aug. 7 at 5:52 PM
$LSTA Kuva will either have to pay $2M (+ litigation) and get nth or find the cash and close the deal
1 · Reply
skyrockets_Inc
skyrockets_Inc Aug. 7 at 5:35 PM
$LSTA 10Q shows 10m cash end of June 30, 2026. 1.2m in costs with workforce reduction, and burn of 3-4m in GA expenses puts this at 5m cash end of Sept 30, 2026. Likely has 7m in cash today + NASDAQ shell worth 7-10m. In an RM scenario the likely value would be 3m cash + NASDAQ shell = 10m or 1.10/share FLOOR valuation, giving ZERO value to assets. The math still supports the current PPS imo
0 · Reply
majsterJoda
majsterJoda Aug. 7 at 11:12 AM
$LSTA this should be priced below 50c
0 · Reply
majsterJoda
majsterJoda Aug. 7 at 11:10 AM
$LSTA cash 8 mil - 70% workforce retention bonusess ... we can say 5 mil
1 · Reply
TwongStocks
TwongStocks Aug. 6 at 8:20 PM
$LSTA 10-Q filed after hours today https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000032001726000038/lsta-20260630.htm • Cash is $10.44M as of June 30th. • They estimate that they will incur approximately $1.2 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits.
0 · Reply
majsterJoda
majsterJoda Aug. 6 at 12:12 PM
$LSTA they have less than 5mil cash this should fall soon
0 · Reply
skyrockets_Inc
skyrockets_Inc Aug. 4 at 5:36 PM
$LSTA PR today is in line w/ expectations of companies next steps. Proceed w/ litigation as discussed in previous filing, put pressure on Kuva (who is still actively working on funding) while proceeding w/ a secondary strategic alternative process likely looking for merger candidates. Option A). Kuva returns with FULLY FUNDED tender offer in 2.50-3.50/share range upfront --> LSTA accepts--> Stock pops--> Lawsuit dropped. Option B). Kuva does not return with offer, or returns with sub-par offer that LSTA rejects (i.e. $1/share range). --> Lawsuit proceeds --> LSTA finds RM candidate (5m in net cash + 5-7m in NASDAQ shell value puts deal value at $1.10/share MIN, w/ no value given to legacy assets). CFO is employed through Dec31 2026 so any deal will likely come months before then. Win-win solution either way imo.
0 · Reply
LandonCapital
LandonCapital Aug. 4 at 11:38 AM
$LSTA https://landoncapital.net/bad-breakups-lisata-nasdaq-lsta-sues-kuva-labs-after-merger-collapse/
0 · Reply
TwongStocks
TwongStocks Aug. 4 at 11:28 AM
$LSTA SEC filing this morning. Reduction in force by 72% effective immediately. https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000114036126031028/ef20079399_8k.htm • Chief Medical Officer, Kristen Buck, was let go. • Chief Accounting Officer, James Nisco, was given a $200K retention bonus for continued employment through Dec 31, 2026. • Lisata filed lawsuit against Kuva Labs in the Court of Chancery of the State of Delaware.
0 · Reply
Gunnar1
Gunnar1 Aug. 4 at 10:41 AM
$LSTA Besides the other items of todays 8k like cutting workforce, this is interesting as well:
0 · Reply
focafoca99
focafoca99 Aug. 4 at 10:26 AM
$LSTA is cutting its workforce by about 72% and terminating its EVP of R&D.
0 · Reply
Gunnar1
Gunnar1 Aug. 3 at 4:10 PM
$LSTA Daily chart. I like the combination of very oversold RSI and KDJ, the Keltner Channel and the trendlines. I know that TA is not always reliable for small cap biotechs, but nevertheless it can be a useful instrument IMO. I'm nibbling at these levels... No advice, you do you.
1 · Reply
skyrockets_Inc
skyrockets_Inc Aug. 3 at 3:48 PM
$LSTA 10-Q should be out this week. By my estimates they should have ~9m in cash. With 9m in cash, minimal burn, and a NASDAQ shell worth 7-8m, this ticker is worth easily 10-12m in a reverse merger scenario, or ~1.30/share floor valuation. This gives no premium to the merger or any value to any of the pipeline assets.
1 · Reply
cocoover1
cocoover1 Aug. 3 at 1:52 PM
$LSTA It's over
1 · Reply
joe77w
joe77w Jul. 31 at 2:47 PM
$LSTA 🙏
0 · Reply
joe77w
joe77w Jul. 31 at 2:38 PM
$LSTA 👌
0 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 31 at 2:38 PM
$LSTA So the key takeaway from below is that Kuva is still actively working on finishing up their financing and it appears based on verbiage that they are very close. IF this financing occurs then they will re-submit a new offer to LSTA in which the LSTA CEO confirmed they are open to receiving. So either Kuva gets the financing or they don't. If they do, this likely goes back above $3/share. If they don't then LSTA likey does a RM transaction w/ a private bio and the downside from here is still limited, currently trading at ~9m market cap. GLTA!
0 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 31 at 2:36 PM
$LSTA Updates: I sent an email to both the LSTA CEO and the Kuva CEO yesterday (separately of course) and I got responses from both. -CEO of Kuva said they are continuing to work on the financing and the plan is to submit a FULLY FUNDED tender offer to LSTA. The offers previous were not fully funded. I asked about the timing of this offer and he said he could not comment on specifics of timing but stated that if it's more than a month that LSTA is likely not to accept. This to me implies that his funding (if he gets it) will happen within a month. He also mentioned that they had requested another extension that LSTA had denied, so the implication was that funding was VERY close. -CEO of LSTA said they are still 'open to legitimate FULLY FUNDED offers from Kuva'. I was afraid maybe the relationship was dead but he confirmed that the possibility is still open if Kuva comes with a fully funded offer.
6 · Reply
Gunnar1
Gunnar1 Jul. 31 at 11:44 AM
$LSTA I loaded some...
0 · Reply
Defen
Defen Jul. 30 at 9:31 PM
$LSTA wow
0 · Reply
joe77w
joe77w Jul. 30 at 8:07 PM
$LSTA I agree with you, there Is value here imo, any potential deal how could delivery less than 3 USD (without CVR), otherwise what, liquidation? Low os, NASDAQ listing and a few millions worth 2 USD imo while CVR premium May be increase to 4/5 at this stage, Just my opinion. Lets see the developments...💪💪💪
1 · Reply